先通医药港股IPO招股书失效

Group 1 - The core viewpoint of the article is that Beijing Xiantong International Pharmaceutical Technology Co., Ltd. (Xiantong Pharmaceutical) submitted its Hong Kong IPO prospectus on May 26, 2025, which has now expired after six months [1] - Xiantong Pharmaceutical is a leader in the Chinese radiopharmaceutical market, focusing on the development and commercialization of innovative radiopharmaceuticals with the potential to be the first listed or best-in-class in China [2] - As of the last feasible date (May 16, 2025), Xiantong Pharmaceutical's pipeline targets three major areas: oncology, neurodegenerative diseases, and cardiovascular diseases, including 15 assets, with four core products being XTR008, XTR006, XTR004, and XTR003 [2]